Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and L…
$16.33+15.08%
报价 2026-11-06
市值
$13.03B
EV
$12.9B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -38.1%
$12.43$26.38
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SMMTSummit Therapeutics Inc. | $13.03B | +15.1% | -82.9% | 0% | – | – | – | |
| MRNAModerna, Inc. | $101.48B | +5.3% | +9.3% | -12.6% | – | – | – | |
| RPRXRoyalty Pharma plc | $29.97B | -0.4% | +14.8% | 100% | 25.6x | 17.1x | 12.1x | |
| ROIVRoivant Sciences Ltd. | $28.08B | +6.2% | – | 81.2% | – | – | – | |
| ASNDAscendis Pharma A/S | $16.9B | +1.3% | – | 86.3% | – | – | – | |
| BBIOBridgeBio Pharma, Inc. | $14.47B | +0.0% | +91.2% | 93.8% | – | – | – | |
| UHSUniversal Health Services, Inc. | $10.1B | -1.6% | +7.1% | 9.6% | 8.1x | 5.8x | 9.1x | Cheap |
| IONSIonis Pharmaceuticals, Inc. | $6.55B | +1.6% | -1.6% | 98.3% | – | 3.1x | – | |
| RNAAvidity Biosciences, Inc. | $142.7M | +0.2% | -61.9% | 100% | – | – | – | |
| 同行中位数 | – | – | +8.2% | 90% | 16.8x | 5.8x | 10.6x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。